Dexcom said revenue for Q4 2023 was $1.03 billion, up 27% from a year earlier, and full-year revenue rose 24% to $3.62 billion. GAAP operating income for Q4 was $216.9 million, and for the full year it was $597.7 million.

1. 01

   Dexcom said revenue for Q4 2023 was $1.03 billion, up 27% from a year earlier, and full-year revenue rose 24% to $3.62 billion. GAAP operating income for Q4 was $216.9 million, and for the full year it was $597.7 million.

2. 02

   The company said GAAP net income for Q4 2023 was $256.3 million, or $0.62 per diluted share, and non-GAAP net income was $202.8 million, or $0.50 per diluted share. Non-GAAP net income excludes, among other items, $13.7 million of intellectual property litigation costs and $78.4 million of tax adjustments.

3. 03

   The company said it held $2.72 billion in cash, cash equivalents and marketable securities as of December 31, 2023, and that its revolving credit facility was not drawn. The balance of long-term senior convertible notes was $2,434.2 million ($1,197.7 million as of year-end 2022).

4. 04

   Dexcom said it reiterated its guidance for fiscal 2024 revenue of approximately $4.15 to 4.35 billion (16 to 21% organic growth), and set new Adjusted EBITDA Margin guidance of approximately 29%. Its Non-GAAP Operating Margin outlook is approximately 20%.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.